drugset / Trial / NCT07019012
Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
Phase 4
Recruiting
170 enrolled
Huazhong University of Science and Technology
Renmin Hospital of Wuhan University · collabTaihe Hospital · collabThe First Affiliated Hospital of Nanchang University · collabWuhan Central Hospital · collabXiangyang No.1 People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the change in glycated hemoglobin (HbA1c) levels from baseline to 24 weeks after the combination therapy of cofrogliptin, metformin and SGLT2i (dapagliflozin) in type 2 diabetes mellitus (T2DM) patients with poor control of glucose level by metformin and SGLT2i combination therapy.
Timeline
- Start
- 2025-07-30
- Primary completion
- 2026-10-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cofrogliptin | Small molecule | — | — |
| Comparator | Linagliptin | Small molecule | — | — |
| Background | Metformin | Small molecule | — | — |